Literature DB >> 2898799

Effects of antidepressants on monoamine transporters.

S Z Langer1, H Schoemaker.   

Abstract

1. Using [3H]antidepressants, high affinity binding sites associated with the neuronal transporter for serotonin, noradrenaline, dopamine and adrenaline have been identified. 2. The association of high affinity [3H]imipramine binding with the serotonin transporter in brain and platelets is well established. Although the exact relationship between the [3H]imipramine recognition site and the serotonin transporter remains to be elucidated, it appears that the [3H]imipramine labelled component of the serotonin transporter represents a novel receptor that functions to modulate serotonin uptake. 3. Most data available to date support the hypothesis that [3H]imipramine binding to platelet represents a biological marker in depression. The majority of studies indicate that the Bmax of platelet [3H]imipramine binding is lower in depressed, untreated patients than in the control population and that this finding is relatively specific to depression. 4. Among the [3H]antidepressant binding sites associated with the other monoaminergic transporters, the recent identification of [3H]desipramine binding to the neuronal transporter for adrenaline offers novel perspectives. Thus, given the high affinity for [3H]desipramine binding to the adrenaline transporter in the frog heart for not only desipramine but also imipramine and the atypical antidepressants mianserin and iprindol, it is possible that an interaction with the adrenaline transporter is of significance to the clinical effects of antidepressant drugs.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2898799     DOI: 10.1016/0278-5846(88)90037-1

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  10 in total

1.  C-terminal region regulates the functional expression of human noradrenaline transporter splice variants.

Authors:  Chiharu Sogawa; Kei Kumagai; Norio Sogawa; Katsuya Morita; Toshihiro Dohi; Shigeo Kitayama
Journal:  Biochem J       Date:  2007-01-01       Impact factor: 3.857

2.  Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.

Authors:  Matthew N Hill; Erica J Carrier; Ryan J McLaughlin; Anna C Morrish; Sarah E Meier; Cecilia J Hillard; Boris B Gorzalka
Journal:  J Neurochem       Date:  2008-07-15       Impact factor: 5.372

3.  Extracellular brain cortical levels of noradrenaline in ischemia: effects of desipramine and postischemic administration of idazoxan.

Authors:  I Gustafson; E J Westerberg; T Wieloch
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

Review 4.  Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  R J Milne; K L Goa
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

5.  Differential effects of K(ATP) channel blockers on [(3)H]-noradrenaline overflow after short- and long-term exposure to (+)-oxaprotiline or desipramine.

Authors:  Klaus Eckhardt; Patrick Roth; Thomas Günter; Sascha Schmidt; Thomas J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-01-18       Impact factor: 3.000

6.  Acquired deficit of forebrain glucocorticoid receptor produces depression-like changes in adrenal axis regulation and behavior.

Authors:  Maureen P Boyle; Judson A Brewer; Michiyo Funatsu; David F Wozniak; Joe Z Tsien; Yukitoshi Izumi; Louis J Muglia
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-27       Impact factor: 11.205

7.  Expression and function of variants of human catecholamine transporters lacking the fifth transmembrane region encoded by exon 6.

Authors:  Chiharu Sogawa; Chieko Mitsuhata; Kei Kumagai-Morioka; Norio Sogawa; Kazumi Ohyama; Katsuya Morita; Katsuyuki Kozai; Toshihiro Dohi; Shigeo Kitayama
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

Review 8.  Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.

Authors:  N P Nair; S K Ahmed; N M Kin
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

9.  Organization of the human serotonin transporter gene.

Authors:  K P Lesch; U Balling; J Gross; K Strauss; B L Wolozin; D L Murphy; P Riederer
Journal:  J Neural Transm Gen Sect       Date:  1994

10.  Inhibitory action of antidepressants on mouse Betaine/GABA transporter (BGT1) heterologously expressed in cell cultures.

Authors:  Chiharu Sogawa; Kazumi Ohyama; Takashi Masuko; Tadashi Kusama; Katsuya Morita; Norio Sogawa; Shigeo Kitayama
Journal:  Int J Mol Sci       Date:  2012-02-24       Impact factor: 6.208

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.